taurine has been researched along with Neoplasms in 44 studies
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Based on evaluated non-clinical studies, taurine ameliorates chemotherapy-induced cardiotoxicity, but its possible interaction with the efficacy of anti-cancer medicines that mostly act through induction of oxidants remains to be elucidated in the future." | 9.12 | The role of taurine on chemotherapy-induced cardiotoxicity: A systematic review of non-clinical study. ( Abdollahi, M; Armandeh, M; Bameri, B; Eghbal, MA; Haghi-Aminjan, H; Hooshangi Shayesteh, MR; Naddafi, M; Samadi, M; Sattari, M, 2021) |
| "To determine if the catheter lock taurolidine can reduce the number of catheter-related bloodstream infections (CRBSI) in pediatric cancer patients with tunneled central venous catheters (CVC)." | 5.17 | Central venous catheters and catheter locks in children with cancer: a prospective randomized trial of taurolidine versus heparin. ( Handrup, MM; Møller, JK; Schrøder, H, 2013) |
| "Based on evaluated non-clinical studies, taurine ameliorates chemotherapy-induced cardiotoxicity, but its possible interaction with the efficacy of anti-cancer medicines that mostly act through induction of oxidants remains to be elucidated in the future." | 5.12 | The role of taurine on chemotherapy-induced cardiotoxicity: A systematic review of non-clinical study. ( Abdollahi, M; Armandeh, M; Bameri, B; Eghbal, MA; Haghi-Aminjan, H; Hooshangi Shayesteh, MR; Naddafi, M; Samadi, M; Sattari, M, 2021) |
| "Taurolidine is an antimicrobial agent that was originally used in the local treatment of peritonitis and was shown to be effective in the prevention of catheter-related bloodstream infections (CR-BSI)." | 2.71 | Taurolidine is effective in the treatment of central venous catheter-related bloodstream infections in cancer patients. ( Koldehoff, M; Zakrzewski, JL, 2004) |
| "Taurolidine has been used as an antimicrobial agent in the clinical setting since the 1970s and thus far appears nontoxic." | 2.46 | The evolving role of taurolidine in cancer therapy. ( Bouchier-Hayes, DJ; Hallihan, P; Neary, PM; Pfirrmann, RW; Redmond, HP; Wang, JH, 2010) |
| "Nonetheless, cancer cells continuously proliferate under such high-stressed conditions through incompletely understood mechanisms." | 1.91 | TUG1-mediated R-loop resolution at microsatellite loci as a prerequisite for cancer cell proliferation. ( Iijima, K; Kataoka, K; Kibe, Y; Kitano, Y; Kobayashi, J; Kondo, Y; Mamiya, A; Miyata, K; Murofushi, Y; Nishimura, T; Ogami, K; Ohka, F; Saito, R; Sato, S; Shinjo, K; Suzuki, HI; Suzuki, MM; Wang, X; Xie, J; Yao, R, 2023) |
| "Taurolidine lock was also safe and effective in treating device colonization." | 1.91 | Taurolidine lock in the treatment of colonization and infection of totally implanted venous access devices in cancer patients. ( Bottos, P; Brescia, F; Da Ros, V; Fabiani, F; Moreal, C; Nadalini, E; Pittiruti, M; Scoppettuolo, G; Zanier, C, 2023) |
| "CD44 knockdown in cancer diminished glutathione, but not HT in tumours." | 1.48 | Gold-nanofève surface-enhanced Raman spectroscopy visualizes hypotaurine as a robust anti-oxidant consumed in cancer survival. ( Hiraoka, N; Hishiki, T; Itoh, M; Kabe, Y; Koike, D; Kubo, A; Morikawa, T; Nagano, O; Nagashima, H; Naya, M; Ohmura, M; Sampetrean, O; Saya, H; Shiota, M; Suematsu, M; Sugiura, Y; Suina, K; Takahashi, H; Takubo, K; Tani, T; Watanabe, H; Yamamoto, T; Yamazoe, S, 2018) |
| "The anticancer-drug cyclophosphamide (CP) is known to have nephrotoxicity." | 1.46 | Potential urinary biomarkers of nephrotoxicity in cyclophosphamide-treated rats investigated by NMR-based metabolic profiling. ( Choi, HK; Hyun, SH; Kim, DH; Kim, JY; Kim, SH; Lee, SG; Lim, SR; Moon, KS; Park, SJ; Sul, D, 2017) |
| "has safe & effective anticancer effects, while commonly used 2000-5000 I." | 1.43 | Optimal Dose of Vitamin D3 400 I.U. for Average Adults has A Significant Anti-Cancer Effect, While Widely Used 2000 I.U. or Higher Promotes Cancer: Marked Reduction of Taurine & 1α, 25(OH)2D3 Was Found In Various Cancer Tissues and Oral Intake of Optimal ( Duvvi, H; Jones, MK; Lu, D; Nihrane, A; Ohki, M; Omura, Y; Shimotsuura, Y; Yapor, D, 2016) |
| "In bladder, renal, and prostate cancer, the reason for the insufficient (." | 1.35 | Apoptosis-inducing high (.)NO concentrations are not sustained either in nascent or in developed cancers. ( Heller, A, 2008) |
| "Treatment with taurine prior to stimulation down-regulated FasL protein expression and partially inhibited apoptosis." | 1.33 | Taurine attenuates CD3/interleukin-2-induced T cell apoptosis in an in vitro model of activation-induced cell death (AICD). ( Bouchier-Hayes, DJ; Condron, CE; Maher, SG; Toomey, DM, 2005) |
| "The pharmacokinetic properties of tauromustine (TCNU) were studied in 31 cancer patients who participated in phase I trials." | 1.28 | Pharmacokinetics of tauromustine in cancer patients. Phase I studies. ( Ellman, M; Gunnarsson, PO; Hansen, HH; Macpherson, JS; Polacek, J; Smyth, JF; Vibe-Petersen, J; Warrington, PS, 1989) |
| "Eighty-four patients with refractory cancer received 12 dose escalations from 10-150 mg/m2 TCNU administered orally every 6 weeks." | 1.27 | Phase I study of TCNU, a novel nitrosourea. ( Cornbleet, MA; Kerr, ME; Leonard, RC; Macpherson, JS; Smyth, JF; Warrington, PS; Whelan, JM, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (29.55) | 18.7374 |
| 1990's | 1 (2.27) | 18.2507 |
| 2000's | 13 (29.55) | 29.6817 |
| 2010's | 10 (22.73) | 24.3611 |
| 2020's | 7 (15.91) | 2.80 |
| Authors | Studies |
|---|---|
| Diamandis, P | 1 |
| Wildenhain, J | 1 |
| Clarke, ID | 1 |
| Sacher, AG | 1 |
| Graham, J | 1 |
| Bellows, DS | 1 |
| Ling, EK | 1 |
| Ward, RJ | 1 |
| Jamieson, LG | 1 |
| Tyers, M | 1 |
| Dirks, PB | 1 |
| Doss, HM | 1 |
| Kim, JY | 2 |
| Kim, KS | 1 |
| Stary, D | 1 |
| Bajda, M | 1 |
| Suzuki, MM | 1 |
| Iijima, K | 1 |
| Ogami, K | 1 |
| Shinjo, K | 1 |
| Murofushi, Y | 1 |
| Xie, J | 1 |
| Wang, X | 1 |
| Kitano, Y | 1 |
| Mamiya, A | 1 |
| Kibe, Y | 1 |
| Nishimura, T | 1 |
| Ohka, F | 1 |
| Saito, R | 1 |
| Sato, S | 1 |
| Kobayashi, J | 1 |
| Yao, R | 1 |
| Miyata, K | 1 |
| Kataoka, K | 1 |
| Suzuki, HI | 1 |
| Kondo, Y | 1 |
| Baliou, S | 1 |
| Kyriakopoulos, AM | 1 |
| Spandidos, DA | 1 |
| Zoumpourlis, V | 1 |
| Dotsenko, O | 1 |
| Shtofel, D | 1 |
| Samadi, M | 1 |
| Haghi-Aminjan, H | 1 |
| Sattari, M | 1 |
| Hooshangi Shayesteh, MR | 1 |
| Bameri, B | 1 |
| Armandeh, M | 1 |
| Naddafi, M | 1 |
| Eghbal, MA | 1 |
| Abdollahi, M | 1 |
| Brescia, F | 1 |
| Pittiruti, M | 1 |
| Scoppettuolo, G | 1 |
| Zanier, C | 1 |
| Nadalini, E | 1 |
| Bottos, P | 1 |
| Moreal, C | 1 |
| Da Ros, V | 1 |
| Fabiani, F | 1 |
| Longo, R | 1 |
| Llorens, M | 1 |
| Goetz, C | 1 |
| Platini, C | 1 |
| Eid, N | 1 |
| Sellies, J | 1 |
| Ouamara, N | 1 |
| Quétin, P | 1 |
| Fragai, M | 1 |
| Comito, G | 1 |
| Di Cesare Mannelli, L | 1 |
| Gualdani, R | 1 |
| Calderone, V | 1 |
| Louka, A | 1 |
| Richichi, B | 1 |
| Francesconi, O | 1 |
| Angeli, A | 1 |
| Nocentini, A | 1 |
| Gratteri, P | 1 |
| Chiarugi, P | 1 |
| Ghelardini, C | 1 |
| Tadini-Buoninsegni, F | 1 |
| Supuran, CT | 1 |
| Nativi, C | 1 |
| Shiota, M | 1 |
| Naya, M | 1 |
| Yamamoto, T | 1 |
| Hishiki, T | 1 |
| Tani, T | 1 |
| Takahashi, H | 1 |
| Kubo, A | 1 |
| Koike, D | 1 |
| Itoh, M | 1 |
| Ohmura, M | 1 |
| Kabe, Y | 1 |
| Sugiura, Y | 1 |
| Hiraoka, N | 1 |
| Morikawa, T | 1 |
| Takubo, K | 1 |
| Suina, K | 1 |
| Nagashima, H | 1 |
| Sampetrean, O | 1 |
| Nagano, O | 1 |
| Saya, H | 1 |
| Yamazoe, S | 1 |
| Watanabe, H | 1 |
| Suematsu, M | 1 |
| Handrup, MM | 1 |
| Møller, JK | 1 |
| Schrøder, H | 1 |
| Möhler, H | 1 |
| Pfirrmann, RW | 2 |
| Frei, K | 1 |
| Omura, Y | 1 |
| Lu, D | 1 |
| Jones, MK | 1 |
| Nihrane, A | 1 |
| Duvvi, H | 1 |
| Yapor, D | 1 |
| Shimotsuura, Y | 1 |
| Ohki, M | 1 |
| Lim, SR | 1 |
| Hyun, SH | 1 |
| Lee, SG | 1 |
| Kim, SH | 1 |
| Park, SJ | 1 |
| Moon, KS | 1 |
| Sul, D | 1 |
| Kim, DH | 1 |
| Choi, HK | 1 |
| Pavlov, VA | 1 |
| Kotomtsev, VV | 1 |
| Doronin, AI | 1 |
| Sabadash, EV | 1 |
| Simon, A | 1 |
| Ammann, RA | 1 |
| Wiszniewsky, G | 1 |
| Bode, U | 1 |
| Fleischhack, G | 1 |
| Besuden, MM | 1 |
| Heller, A | 1 |
| Sadzuka, Y | 1 |
| Matsuura, M | 1 |
| Sonobe, T | 1 |
| Neary, PM | 1 |
| Hallihan, P | 1 |
| Wang, JH | 1 |
| Bouchier-Hayes, DJ | 2 |
| Redmond, HP | 1 |
| Chromik, AM | 1 |
| Daigeler, A | 1 |
| Bulut, D | 1 |
| Flier, A | 1 |
| May, C | 1 |
| Harati, K | 1 |
| Roschinsky, J | 1 |
| Sülberg, D | 1 |
| Ritter, PR | 1 |
| Mittelkötter, U | 1 |
| Hahn, SA | 1 |
| Uhl, W | 1 |
| Ozgen, U | 1 |
| Türköz, Y | 1 |
| Stout, M | 1 |
| Ozuğurlu, F | 1 |
| Pelik, F | 1 |
| Bulut, Y | 1 |
| Aslan, M | 1 |
| Ravindranath, Y | 1 |
| Savaşan, S | 1 |
| GREEN, JP | 1 |
| DAY, M | 1 |
| ROBINSON, JD | 1 |
| SONGSTER, CL | 1 |
| SCHOCHET, SS | 1 |
| FARBER, E | 1 |
| TURNER, FP | 1 |
| BRUM, VC | 1 |
| PAQUETTE, WW | 1 |
| WELDEN, RB | 1 |
| Koldehoff, M | 1 |
| Zakrzewski, JL | 1 |
| Maher, SG | 1 |
| Condron, CE | 1 |
| Toomey, DM | 1 |
| Tome, ME | 1 |
| Briehl, MM | 1 |
| Lutz, NW | 1 |
| Jacobi, CA | 2 |
| Menenakos, C | 1 |
| Braumann, C | 2 |
| Kim, C | 1 |
| Gupta, RC | 1 |
| Rosado, JO | 1 |
| Salvador, M | 1 |
| Bonatto, D | 1 |
| Tangermann, J | 1 |
| Müller, JM | 1 |
| Dubiel, W | 1 |
| Láng, I | 1 |
| Feuer, L | 1 |
| Nékám, K | 1 |
| Perl, A | 1 |
| Szigeti, A | 1 |
| Gergely, P | 1 |
| Fehér, J | 1 |
| Lin, JK | 1 |
| Liaw, KY | 1 |
| Kamada, S | 1 |
| Maeda, M | 1 |
| Tsuji, A | 1 |
| Baldetorp, L | 1 |
| Mårtensson, J | 1 |
| Hack, V | 1 |
| Schmid, D | 1 |
| Breitkreutz, R | 1 |
| Stahl-Henning, C | 1 |
| Drings, P | 1 |
| Kinscherf, R | 1 |
| Taut, F | 1 |
| Holm, E | 1 |
| Dröge, W | 1 |
| Gunnarsson, PO | 1 |
| Vibe-Petersen, J | 2 |
| Macpherson, JS | 2 |
| Warrington, PS | 2 |
| Polacek, J | 1 |
| Ellman, M | 1 |
| Hansen, HH | 2 |
| Smyth, JF | 2 |
| Workman, P | 1 |
| Bork, E | 1 |
| Møller, H | 1 |
| Kerr, ME | 1 |
| Whelan, JM | 1 |
| Cornbleet, MA | 1 |
| Leonard, RC | 1 |
| Moroni, F | 1 |
| Guidotti, A | 1 |
| Mugelli, A | 1 |
| Mannaioni, PF | 1 |
| Nishida, H | 1 |
| Tanabe, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised Study of Taurolock for the Locking of Tunneled Central Venous Catheters in Children With Malignant Diseases.[NCT00735813] | Phase 3 | 129 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Prospective, Randomized, Controlled Trial Evaluating the Efficacy of a Lock-therapy With a Solution of Taurolidine/Citrate (TauroLock) vs Standard Saline Solution for the Primary Prevention of Catheter-related Infections (CLI) in Adult Patients Wtih a Non[NCT02279121] | 162 participants (Actual) | Interventional | 2014-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for taurine and Neoplasms
| Article | Year |
|---|---|
Taurine and Creatine Transporters as Potential Drug Targets in Cancer Therapy.
Topics: Creatine; Ligands; Membrane Transport Proteins; Neoplasms; Taurine | 2023 |
Role of taurine, its haloamines and its lncRNA TUG1 in both inflammation and cancer progression. On the road to therapeutics? (Review).
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Cell Proliferation; Disease Models, Animal | 2020 |
The role of taurine on chemotherapy-induced cardiotoxicity: A systematic review of non-clinical study.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Antioxidants; Apoptosis; Cardiotoxicity; H | 2021 |
Redox-directed cancer therapeutics: Taurolidine and Piperlongumine as broadly effective antineoplastic agents (review).
Topics: Antineoplastic Agents; Apoptosis; Cell Survival; Dioxolanes; Humans; Neoplasms; Oxidation-Reduction; | 2014 |
The evolving role of taurolidine in cancer therapy.
Topics: Animals; Antineoplastic Agents; Humans; Neoplasms; Taurine; Thiadiazines | 2010 |
Taurolidine--a new drug with anti-tumor and anti-angiogenic effects.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Prolifera | 2005 |
Taurine analogues and taurine transport: therapeutic advantages.
Topics: Aging; Animals; Antioxidants; Behavior; Bile Acids and Salts; Body Temperature; Bone and Bones; Card | 2006 |
Importance of the trans-sulfuration pathway in cancer prevention and promotion.
Topics: Adenosylhomocysteinase; Cystathionine beta-Synthase; Cystathionine gamma-Lyase; Glutathione; Humans; | 2007 |
Novel anti-angiogenic compounds for application in tumor therapy - COP9 signalosome-associated kinases as possible targets.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; COP9 Signalosome Complex; Curcumin; Drug Sc | 2008 |
TCNU: a ray of hope for designer nitrosoureas?
Topics: Antineoplastic Agents; Humans; Neoplasms; Nitrosourea Compounds; Taurine | 1987 |
3 trials available for taurine and Neoplasms
| Article | Year |
|---|---|
Taurolidine/Citrate Lock Therapy for Primary Prevention of Catheter-Related Infections in Cancer Patients: Results of a Prospective, Randomized, Phase IV Trial (ATAPAC).
Topics: Aged; Anti-Infective Agents; Biofilms; Catheter-Related Infections; Catheters, Indwelling; Central V | 2017 |
Central venous catheters and catheter locks in children with cancer: a prospective randomized trial of taurolidine versus heparin.
Topics: Adolescent; Adult; Anti-Infective Agents; Anticoagulants; Central Venous Catheters; Child; Child, Pr | 2013 |
Taurolidine is effective in the treatment of central venous catheter-related bloodstream infections in cancer patients.
Topics: Adult; Anti-Infective Agents; Bacteremia; Catheterization, Central Venous; Female; Humans; Male; Neo | 2004 |
31 other studies available for taurine and Neoplasms
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic | 2007 |
Taurine Supplementation Inhibits the Expression of Atrogin-1 and MURF-1, Protein Degradation Marker Genes, in Skeletal Muscle of C26-Induced Cachexia Mouse Model.
Topics: Animals; Cachexia; Dietary Supplements; Disease Models, Animal; Mice; Muscle, Skeletal; Muscular Atr | 2022 |
TUG1-mediated R-loop resolution at microsatellite loci as a prerequisite for cancer cell proliferation.
Topics: Cell Proliferation; DNA Replication; Humans; Microsatellite Repeats; Neoplasms; R-Loop Structures; T | 2023 |
In Silico Prediction of Metabolic Fluxes in Cancer Cells with Altered S-adenosylmethionine Decarboxylase Activity.
Topics: Adenosine Triphosphate; Adenosylmethionine Decarboxylase; Antineoplastic Agents; Computer Simulation | 2021 |
Taurolidine lock in the treatment of colonization and infection of totally implanted venous access devices in cancer patients.
Topics: Catheter-Related Infections; Catheterization, Central Venous; Central Venous Catheters; Humans; Neop | 2023 |
Lipoyl-Homotaurine Derivative (ADM_12) Reverts Oxaliplatin-Induced Neuropathy and Reduces Cancer Cells Malignancy by Inhibiting Carbonic Anhydrase IX (CAIX).
Topics: Antineoplastic Agents; Carbonic Anhydrase Inhibitors; Carbonic Anhydrase IX; Cell Line, Tumor; Drug | 2017 |
Gold-nanofève surface-enhanced Raman spectroscopy visualizes hypotaurine as a robust anti-oxidant consumed in cancer survival.
Topics: Animals; Antioxidants; Female; Glutathione; Gold; Humans; Liver; Male; Metal Nanoparticles; Mice; Mi | 2018 |
Optimal Dose of Vitamin D3 400 I.U. for Average Adults has A Significant Anti-Cancer Effect, While Widely Used 2000 I.U. or Higher Promotes Cancer: Marked Reduction of Taurine & 1α, 25(OH)2D3 Was Found In Various Cancer Tissues and Oral Intake of Optimal
Topics: Adult; Cholecalciferol; Dietary Supplements; Dose-Response Relationship, Drug; Female; Humans; Male; | 2016 |
Potential urinary biomarkers of nephrotoxicity in cyclophosphamide-treated rats investigated by NMR-based metabolic profiling.
Topics: Animals; Biomarkers; Cyclophosphamide; Humans; Isoleucine; Kidney; Leucine; Magnetic Resonance Spect | 2017 |
Antioxidant and Antimutagenic Metabolites in Animals with Opposite Sensitivity to Tuberculosis Mycobacteria and Mutagenic Xenobiotics.
Topics: Animals; Disease Susceptibility; Ethanolamine; Ethanolamines; Glutathione; Guinea Pigs; Liver; Methi | 2016 |
Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patients.
Topics: Adolescent; Adult; Anti-Infective Agents; Catheterization, Central Venous; Child; Child, Preschool; | 2008 |
Apoptosis-inducing high (.)NO concentrations are not sustained either in nascent or in developed cancers.
Topics: Apoptosis; Arginase; Erythrocytes; Humans; Neoplasms; Neutrophils; Nitric Oxide; Nitric Oxide Syntha | 2008 |
The effect of taurine, a novel biochemical modulator, on the antitumor activity of doxorubicin.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Doxorubicin; Drug Synergism; Humans; Male; Membran | 2009 |
Comparative analysis of cell death induction by Taurolidine in different malignant human cancer cell lines.
Topics: Acetylcysteine; Antineoplastic Agents; Caspases; Cell Death; Cell Line, Tumor; Cell Survival; Dose-R | 2010 |
Degradation of vincristine by myeloperoxidase and hypochlorous acid in children with acute lymphoblastic leukemia.
Topics: Acetaminophen; Acute Disease; Analgesics, Non-Narcotic; Antineoplastic Agents, Phytogenic; Case-Cont | 2003 |
Some acidic substances in neoplastic mast cells and in the pineal body.
Topics: Cerebrosides; Histamine; Mast Cells; Neoplasms; Neoplasms, Experimental; Neuraminic Acids; Pineal Gl | 1962 |
METABOLISM OF BILE COMPONENTS DURING HEPATOCARCINOGENESIS. I. CONJUGATION OF CHOLIC ACID IN VITRO IN EXPERIMENTAL LIVER CARCINOGENESIS.
Topics: Bile; Bile Acids and Salts; Carcinogenesis; Cholic Acid; Ethionine; Fluorenes; In Vitro Techniques; | 1963 |
THE URINARY EXCRETION OF FREE TAURINE IN ACUTE AND CHRONIC DISEASE, FOLLOWING SURGICAL TRAUMA, AND IN PATIENTS WITH ACUTE ALCOHOLISM.
Topics: Adrenal Cortex Hormones; Alcoholism; Biliary Tract; Biomedical Research; Cholecystitis; Cholelithias | 1964 |
Taurine attenuates CD3/interleukin-2-induced T cell apoptosis in an in vitro model of activation-induced cell death (AICD).
Topics: Analysis of Variance; Antibodies, Monoclonal; Apoptosis; CD3 Complex; Fas Ligand Protein; Flow Cytom | 2005 |
Increasing the antioxidant defense in WEHI7.2 cells results in a more tumor-like metabolic profile.
Topics: Adenosine Triphosphate; Amino Acids; Animals; Antioxidants; Aspartic Acid; Cell Line, Tumor; Glycoly | 2005 |
Accumulation of taurine in tumor and inflammatory lesions.
Topics: Animals; Cell Line; Inflammation; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mice; N | 2006 |
[Effect of Litoralon therapy on the lymphocytotoxicity in patients with malignant tumors].
Topics: Antibody-Dependent Cell Cytotoxicity; Cytotoxicity Tests, Immunologic; Cytotoxicity, Immunologic; Gl | 1984 |
Rapid qualitative and quantitative determinations of urinary amino acids by thin layer and high performance liquid chromatography with dabsyl chloride.
Topics: Adult; Amino Acids; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Female; Humans | 1982 |
Fluorescence high-performance liquid chromatographic determination of free and conjugated bile acids in serum and bile using 1-bromoacetylpyrene as a pre-labeling reagent.
Topics: Bile; Bile Acids and Salts; Chromatography, High Pressure Liquid; Fluorescent Dyes; Glycine; Humans; | 1983 |
Urinary excretion of inorganic sulfate, ester sulfate, total sulfur and taurine in cancer patients.
Topics: Aged; Creatinine; Female; Humans; Male; Middle Aged; Neoplasms; Sulfates; Sulfur; Sulfuric Acid Este | 1980 |
Cystine levels, cystine flux, and protein catabolism in cancer cachexia, HIV/SIV infection, and senescence.
Topics: Adipose Tissue; Adolescent; Adult; Aging; Animals; Cachexia; CD4 Lymphocyte Count; Citrulline; Cysti | 1997 |
Pharmacokinetics of tauromustine in cancer patients. Phase I studies.
Topics: Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Evaluation; Humans; Neoplasms; Nitroso | 1989 |
A phase I clinical evaluation of 1-(2-chloroethyl)-3-[2-(dimethylaminosulphonyl)ethyl]-1-nitrosou rea (TCNU).
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Evaluation; H | 1987 |
Phase I study of TCNU, a novel nitrosourea.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Evaluation; F | 1987 |
Effects of some amino acids on the content and uptake of histamine by neoplastic mast cells in vitro.
Topics: Amino Acids; Aminobutyrates; Animals; Carboxylic Acids; Clone Cells; Culture Media; Glutamates; Hist | 1974 |
[Clinical experience with taurine in radiotherapy].
Topics: Adult; Aged; Child; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Radiotherapy; Taurine | 1970 |